Ann: ACW XanaCIDD depression trial results expected early August, page-76

I thought the price may have settled around the 5c range as it had just before the Xanadu trial results. Maybe just maybe Dr Gourlay’s comments in the fund raising webinar are having some positive reaction to the SP. remember this has the potential to be a bigger earner than AD. Many yrs back the ex CEO mentioned that the company had the potential tto be taken over by Pharma on positive depression results when ACW were looking at other neurological disorders to trial Xanamem. I think at the time he may have been a bit exuberant as this was mentioned during the Xanahes results for memory. Though he was shown the door some time later. GLTOH .